RESEARCH-POSTERS.COM/APHA APHA POSTER TEMPLATE This template will help provide time-saving assistance to you in developing a professional appearing 48”x72” poster. Research-Posters.com is proud to be chosen as the preferred poster printing vendor by the American Public Health Association (APHA) for the fourth consecutive year. Our poster prices (which are up to 33% less than FedEx Kinko's) include ground shipping to APHA's Annual Meeting & Exposition in San Francisco and storage until you are ready to present your poster. No other poster printing service will allow you the convenience of having your poster waiting for you onsite at the APHA poster sessions. The hassle-free convenience of using our service will also help you avoid hidden charges (checked bag fees, hotel storage fees and receiving fees) that can occur by transporting your poster to San Francisco. Using Research-Posters.com to print your poster will allow you the convenience you hope for while attending an out of town meeting and will give you the comfort of knowing that you will stay within budget by avoiding hidden costs that can arise. POSTER PICK-UP HOURS* (at Moscone Center in San Francisco) Sunday (10/28) :00am - 5:00pm Monday (10/29 ) :00am - 5:00pm Tuesday (10/30 ) :00am - 5:00pm Wednesday (10/31 ) :00am - 9:30am * PICK-UP LOCATION AND ANY CHANGES TO POSTER PICK-UP HOURS WILL BE PUBLISHED AT RESEARCH-POSTERS.COM/APHA CLOSER TO THE CONFERENCE DATE Once you design your poster, all you need to do is order your poster at for our first-class printing services and the convenience of picking up your poster onsite at the APHA 140 th Annual Meeting & Exposition in San Francisco. POSTER ORDERS RECEIVED BEFORE 8:00PM PST ON OCTOBER 8 TH WILL RECEIVE DISCOUNTED EARLY-BIRD PRICING. ORDERS RECEIVED AFTER OCTOBER 8 TH BUT BEFORE 8:00PM PST ON OCTOBER 18 TH WILL BE CHARGED AT OUR NORMAL APHA RATES. PLEASE CONTACT US AT FOR ORDERS BEING SUBMITTED AFTER OCTOBER 18 * * * BOTH THIS SECTION AND THE ONE TO THE RIGHT WILL NOT BE PRINTED * * * HOW TO USE THIS TEMPLATE CHANGING THE LAYOUT This template has several different column layouts. Right-click your mouse on the template background and click on “Layout” to see different layout options. The column widths in these preformatted layouts cannot be moved but advanced users can modify any layout by clicking on the VIEW menu and then on SLIDE MASTER. CHANGING THE COLOR SCHEME To change the color scheme of this template click on the DESIGN menu and then on COLORS. You can choose from the provided color combinations or you can create your own. USING PLACEHOLDERS To add text to this template, click inside a placeholder and type in or paste your text. To move a placeholder, click on it once to select it, then place your cursor on its frame and then click and hold as you drag it to its new location. Resize the placeholder, if necessary. Placeholders for headers, text and graphics can be found below: HEADER PLACEHOLDER Move this preformatted header placeholder to the poster area to add another header. Use headers to separate topics or concepts within your presentation. TEXT PLACEHOLDER Move below text placeholder onto your poster to add a new text box. GRAPHIC PLACEHOLDER Move the below graphic placeholder onto your poster, size it first, and then click it to add a picture to the poster. IMPORTING EXTERNAL TEXT & GRAPHICS TEXT: Paste or type your text into a pre-existing text box or drag in a new text box from above. Move and/or resize it as you desire. PHOTOS: Drag in a picture placeholder, size it first, click in it and insert a photo from the menu. TABLES: You can copy and paste a table from an external document onto this poster template. To adjust the way the text fits within the cells of a table that has been pasted, right-click on the table, click FORMAT SHAPE then click on TEXT BOX and change the INTERNAL MARGIN values to 0.25 REVIEWING QUALITY OF GRAPHICS Go to View on the menu bar, then choose Zoom, 200%. This is a good representation of what your poster will look like when printed. Scroll left, right, up, and down looking for “grainy” images that may need to be fixed and re-imported. SAVING YOUR WORK Click on the Office Button and hover over Save As. Choose the PDF or XPS option with standard publishing. Name your poster file and submit the resulting PDF version of your poster with your order. Implementation of a Replicable Animal-Assisted Intervention Protocol in Pediatric Oncology Settings In the past 20 years, childhood cancer rates have increased slightly, but advances in treatment options have led to greater survivorship for nearly all forms of childhood cancers. These improved survival rates have brought forth a plethora of new challenges for both children and families as they undergo cancer treatment, often a long-term process. In an effort to address these complex medical, behavioral and psychosocial issues, American Humane Association, with funding from Pfizer Animal Health, has partnered with three children's hospitals across the country to implement a complementary health practice in the form of a replicable animal-assisted therapy intervention. For the purposes of this pilot study, we are utilizing a randomized control trial design. We anticipate that this landmark study, Canines and Childhood Cancer (CCC): Examining the Effects of Therapy Dogs with Childhood Cancer Patients and their Families, will provide valuable information to the growing evidence-base in the field of animal-assisted interventions. ABSTRACT STUDY AIMS To address the feasibility of conducting a randomized control trial utilizing AAT within a pediatric healthcare setting To determine how to address issues of scientific integrity and protocol fidelity To ensure the validity of the six month/26 week pilot study To develop recommendations for revisions to the protocol leading up to a final research protocol for a full month clinical trial To provide sites with an opportunity to become familiar with—and trained in—the aspects of the protocol in preparation for possible participation in the full clinical trial PILOT STUDY GOALS Children Observational Scale of Behavioral Distress (OSBD): a scale developed to measure children’s responses to painful medical procedures Polar RS800CX training watch/Polar WearLink W.I.N.D. transmitter (outpatient) or an EKG (inpatient): to measure heart rate variability Blood pressure cuff: to measure systolic and diastolic blood pressure Parents/Primary Caregivers State Trait Anxiety Inventory (STAI): a questionnaire that differentiates between current state anxiety and more inherent trait or character anxiety Pediatric Inventory for Parents (PIP): a questionnaire to specifically measure stress in parents/caregivers who are dealing with a critically ill child, particularly a child with cancer Polar RS800CX training watch/Polar WearLink W.I.N.D. transmitter: to measure heart rate variability Measuring Distress in Therapy Dogs Handler self-reports: regarding their dog’s behavior, the dog’s reaction to the family (and vice versa), activities that took place during the session, session participants, and other pertinent notes Salivary cortisol: handlers will collect their dog’s saliva after each session (these will be compared to a baseline measurement obtained at or before the animal-handler team’s enrollment in the study) AAT Ethogram: video cameras may be used to record sessions so that independent observers can document the dog’s behavioral cues utilizing the AAT Ethogram MEASURES METHODS We are utilizing a randomized controlled trial and multi-site design at three hospitals for the pilot study. One group at each hospital site will receive the AAT intervention and one group will not; both will receive the standard-of-care for ALL patients. Therapy dogs are to be introduced no later than treatment day 15, but preferably at the time of diagnosis or within the first week. Each child will be matched with same animal-handler team over the course of the pilot. The AAT session will last for approximately 20 minutes on a weekly basis or during the child’s regularly scheduled appointment - visits will be more frequent during the first month of the child’s treatment. The data collection process will be more intensive during the initial induction therapy, occurring during the first month after the child’s diagnosis. After the induction therapy phase has been completed, the data collection process will become less frequent with the battery of measures being administered during the critical treatment days outlined in the COG protocol for up to 26 weeks, until the study’s completion or the patient/family drops out, whichever occurs first (see chart below). ACKNOWLEDGEMENTS/CONTACT INFORMATION All of the information presented is owned by Pfizer Animal Health and American Humane Association. To learn more about the study or to get involved please contact: Ashleigh Ruehrdanz Molly Jenkins, M.S.W. Research and Evaluation Specialist & IRB Administrator Research Analyst, Children’s Innovation Institute Children’s Innovation Institute, American Humane Association American Humane Association p: (303) | p: (720) | Amy McCullough, M.A. John Fluke, Ph.D. (Principal Investigator) National Director, Animal-Assisted Therapy Associate Director for Systems Research and Evaluation American Humane Association Department of Pediatrics, Kempe Center for the Prevention p: | and Treatment of Child Abuse & p: (303) | Empirical evidence shows that interaction with animals during can be beneficial in a variety of settings (Fine, 2010; Friedmann, Son, & Tsai, 2010; McCardle, McCune, Griffin, Esposito & Freund, 2011; Nimer & Lundahl, 2007; Serpell, 2006; Tsai, Friedmann, & Thomas, 2010; Wells, 2009). We aim to document the health and well-being effects of AAT by determining: The biological and psychosocial impacts of therapy dogs on children with cancer The biological and psychosocial impacts of therapy dogs on families (primarily caregivers, such as parents, grandparents or other relatives) of children with cancer The biological and behavioral impacts of AAT sessions on participating therapy dogs Ashleigh Ruehrdanz, Molly Jenkins, M.S.W., Amy McCullough, M.A., and John Fluke, Ph.D. HYPOTHESES Children H 1 : Pediatric cancer patients with Acute Lymphoblastic Leukemia (ALL) who receive AAT will experience less distress throughout the course of their treatment sessions than patients who do not receive AAT. Families (parent(s)/primary caregivers) H 2 : Parent(s)/primary caregivers of pediatric cancer patients with ALL who receive AAT will experience less distress throughout the course of their child’s treatment sessions than parent(s)/primary caregivers of patients who do not receive AAT. Therapy Dogs H 3 : Participating therapy dogs will exhibit minimal distress over the course of the CCC study. STUDY POPULATION Our patient population for the pilot is children aged 3 through 11 years who are newly diagnosed with Acute Lymphoblastic Leukemia (ALL). Based on existing admissions data from each of the three pilot sites, the research team anticipates that up to 20 patients (or ~6-7 patients/site) may participate in the six month/26 week pilot trial. The patient population was selected for the following reasons: ALL is the most common form of childhood cancer ALL patients typically experience a common treatment protocol under the Children’s Oncology Group, that is consistently used at all sites enrolled in the pilot study Aside from consistently utilized medication, ALL treatment does not involve procedures that may directly impact neural function or development Age three is within the peak age range for diagnosis of ALL According to focus group findings, older children and adolescents (e.g., > age 11) may not have a strong emotional response to therapy dogs The parent/caregiver population for the pilot will be the individual(s) who are identified as the eligible child’s primary caregiver.(s) The study coordinator will identify these individuals after their child has been determined to be eligible for the study. The animal-handlers and their dogs will make up the other segment of our study population. The animal-handlers will be recruited and selected by American Humane Association staff in conjunction with the study coordinator, volunteer coordinators and AAT volunteer leads at each of the pilot sites.